

# Virocure Patents Registered

	Status	Patent title	Country	Patent Number & Registration Date	Pipeline	Main Reference
1	R	Tumor suppressor-based susceptibility of hyperproliferative cells to oncolytic viral therapy	Korea	10-1585702 (2016.1.8)	RC402(IT) RC402(PO) MC509N	Use of Reovirus or Myxoma virus for cancer therapy
2	R		Japan	5748656 (2015.5.22)		
3	R		China	102124335 (2014.7.30)		
4	R	Squirrel poxvirus as an oncolytic agent	Korea	10-1370620 (2014.2.27)	SC717	Use of squirrel poxvirus for cancer therapy
5	R	Attenuated reovirus for treatment of proliferative disorders	US	10.260.049 (2019.4.16)	RP116	Use of attenuated reovirus for cancer therapy
6	R		US	10.668.119 (2020.6.2)		Use of attenuated reovirus for cancer therapy
7	R	Attenuated reoviruses for selection of cell populations	US	10.369.171 (2019.8.6)		Use of attenuated reovirus and stem cell for cancer therapy
8	R	Squirrel poxvirus and myxoma poxvirus for cancer treatment	Korea	10-2093623 (2020.3.20))	SC717+MC509	Use of squirrel poxvirus and myxoma poxvirus for cancer treatment
9	R	Methods for virus production using BHK-21 cell	Korea	Registration # TBA	RC402(IT) RC402(PO)	Production Methods of Reovirus using BHK-21 cell